### SALI-4
External request:
Submission from Genentech Inc., to recommend entrectinib and appropriate NTRK gene fusion testing for the treatment of NTRK gene fusion-positive salivary gland tumors, including mammary analogue secretory carcinoma (MASC).

**Panel Discussion/References**
Based on a review of data and discussion, the panel consensus supported the inclusion of entrectinib as an option for metastatic NTRK gene fusion-positive salivary gland tumors, including mammary analogue secretory carcinoma (MASC).

See Submission for references.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0</td>
<td>0</td>
<td>8</td>
</tr>
</tbody>
</table>

### CHEM-A (2 of 6)
External request:
Submission from Merck & Co., Inc., to consider:

1. The inclusion of pembrolizumab monotherapy as a category 1 first-line treatment recommendation in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that expresses PD-L1 combined positive score (CPS) ≥1.
2. The inclusion of pembrolizumab in combination with chemotherapy with a platinum and fluorouracil as a category 1 first-line treatment recommendation in patients with recurrent or metastatic HNSCC.

**Panel Discussion/References**

1. Based on a review of data and discussion, the panel consensus supported moving single-agent pembrolizumab from the "useful in certain circumstances" options to the list of "preferred regimens" for patients with PD-L1 positive tumors. The panel consensus was to make no change to the current category of evidence and wait for publication of the data.

2. Based on a review of the data and discussion, the panel consensus was to make no change to the current category of evidence for pembrolizumab in combination with platinum-based chemotherapy and wait for publication of the data.

See Submission for references.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0</td>
<td>0</td>
<td>8</td>
</tr>
</tbody>
</table>